Company research
CITIUS ONCOLOGY, INC.
CIK 1851484Updated Sep 27, 2026
SecurityCTOR · NASDAQ · equity
Name history
TenX Keane Acquisition · through Aug 5, 2024
CTOR price & chart
Loading TradingView…
NASDAQ:CTOR on TradingView ↗About the company
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL who had had at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
In the news
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update News provided by Citius Oncology, Inc. Dec 23, 2025, 16:30 ET Share this article Share to X Share this article Share to X Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 ↗
Recent filings
ARS filing
DEF 14A filing
424B3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 100,942,881Source | 84,368,878Source | 72,623,594Source | 68,190,364Source |
| Current assets: | ||||
| Inventory, NetUSD | 22,286,693Source | 8,268,766Source | — | — |
| Assets, CurrentUSD | 27,542,881Source | 10,968,878Source | 58,200Source | 377,344Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 56,076,650Source | 38,228,540Source | — | — |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,351Source | 7,155Source | 167Source | 242Source |
| Additional Paid in CapitalUSD | 108,897,836Source | 85,411,771Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -64,039,956Source | -39,278,587Source | -1,987,729Source | 345,266Source |
| Stockholders' Equity Attributable to ParentUSD | 44,866,231Source | 46,140,339Source | -1,987,562Source | 345,508Source |
| Liabilities and EquityUSD | 100,942,881Source | 84,368,878Source | 72,623,594Source | 68,190,364Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 49,491,579Source | 32,700,429Source | 2,045,762Source | 31,836Source |
| Accounts Payable, CurrentUSD | 13,234,684Source | 3,711,622Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | 2,784,960Source | 1,728,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 4,093,124Source | — | 375,886Source | — |
| Deferred Tax Liabilities, NetUSD | 2,784,960Source | 1,728,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,320,419Source | 7,498,817Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 12,649,207Source | 2,133,871Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | 1,056,960Source | 576,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,492,046Source | 126,353Source | -601,304Source | -47,968Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,750,000Source | -5,000,000Source | -1,320,000Source | -67,320,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 15,166,842Source | 4,873,759Source | 1,664,875Source | 67,657,143Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | -256,429Source | 289,175Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,924,908Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 187,389Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,116,678Source | 7,498,817Source | — | — |
| General and Administrative ExpenseUSD | 8,783,997Source | 8,148,929Source | 1,013,070Source | 138,115Source |
| Income Tax Expense (Benefit)USD | 1,056,960Source | 576,000Source | — | — |
| InterestExpenseNonoperatingUSD | 218,032Source | — | — | — |
| Investment Income, InterestUSD | 36,373Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -24,761,369Source | -21,148,747Source | 2,419,304Source | 380,811Source |
| Noncash Merger Related CostsUSD | 2,753,795Source | — | — | — |
| Nonoperating Income (Expense)USD | -181,659Source | — | 3,432,374Source | 518,926Source |
| Operating ExpensesUSD | 23,522,750Source | 20,572,747Source | — | — |
| Proceeds from Contributed CapitalUSD | — | 3,827,944Source | — | — |
| Proceeds from Issuance of Common StockUSD | 15,166,842Source | — | — | 66,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -23,522,750Source | — | -1,013,070Source | -138,115Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -23,704,409Source | -20,572,747Source | — | — |
| Income Tax Expense (Benefit)USD | 1,056,960Source | 576,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -24,761,369Source | -21,148,747Source | 2,419,304Source | 380,811Source |
| Earnings Per Share, BasicUSD per share | -0.34Source | -0.31Source | 0.27Source | 0.12Source |
| Earnings Per Share, DilutedUSD per share | -0.34Source | -0.31Source | 0.27Source | 0.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 73,267,969Source | 68,053,607Source | 6,600,000Source | 1,865,478Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 73,267,969Source | 68,053,607Source | 6,600,000Source | 1,341,758Source |
| Interest Expense (non-operating)USD | 218,032Source | — | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 8,783,997Source | 8,148,929Source | 1,013,070Source | 138,115Source |
| Interest ExpenseUSD | 218,032Source | — | — | — |
| Investment Income, InterestUSD | 36,373Source | — | — | — |
| Nonoperating Income (Expense)USD | -181,659Source | — | 3,432,374Source | 518,926Source |
| Operating ExpensesUSD | 23,522,750Source | 20,572,747Source | — | — |
| Other ExpensesUSD | 114,185Source | 121,570Source | — | — |
| Other General and Administrative ExpenseUSD | 2,201,742Source | 1,846,202Source | 120,000Source | 21,666Source |
| Research and Development ExpenseUSD | 6,418,334Source | 4,925,001Source | — | — |
Offerings
Registration 333-288656
- Gross proceeds
- 9000000.0
- Net proceeds
- 8370000.0
- Deal price
- 1.32
- Shares
- 6818182
- Offering price
- at-the-market
- Ticker
- CTOR
Filing attachments
ea030222601ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030222601ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., August 14, 2026 /PRNewswire/ -- Citius Onc…
Read attachment ↗ea030145601ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ea030145601ex99-1.htm PRESS RELEASE, DATED AUGUST 12, 2026 Exhibit 99.1 Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., August 12, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph. D., J.D., as…
Read attachment ↗ea030037101ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ea030037101ex99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 Exhibit 99.1 Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR’s near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., August 5, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncolog…
Read attachment ↗ea029290301ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 ea029290301ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patien…
Read attachment ↗ea029103501ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ea029103501ex99-1.htm PRESS RELEASE, DATED MAY 15, 2026 Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update $5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimbursement denials 83% of target accounts on formulary or in review CRANFORD, N.J., May 15, 2026 - Citius Oncology, …
Read attachment ↗ea028929701ex4-1.htm · 8-K · 2026-05-06
EX-4.1 2 ea028929701ex4-1.htm FORM OF NEW WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR P…
Read attachment ↗